The global infectious disease diagnostics market is projected to reach USD 42.20 billion by 2030, up from USD 26.58 billion in 2025, growing at a CAGR of 9.7% during the forecast period, according to the latest MarketsandMarkets™ report.
The market’s expansion is fueled by the rising global incidence of infectious diseases, growing demand for early and accurate testing, and technological innovations in molecular diagnostics and point-of-care (PoC) testing.
🌍 Market Overview: The Rising Demand for Accurate and Rapid Disease Testing
The growing global burden of infectious diseases—including HIV, tuberculosis, influenza, hepatitis, and healthcare-associated infections (HAIs)—has accelerated the adoption of advanced diagnostic technologies.
Recurring outbreaks, such as those caused by novel respiratory viruses, and the emergence of antimicrobial resistance (AMR), have underscored the importance of rapid and precise diagnostic tools.
Key Growth Drivers:
- Increasing global prevalence of infectious and emerging diseases
- Growing focus on early detection and personalized treatment
- Continuous technological advancements in molecular and PoC diagnostics
- Expansion of healthcare infrastructure in developing economies
- Rising government investments in public health surveillance
Together, these factors are driving strong growth across clinical laboratories, hospitals, and research institutions, as healthcare systems prioritize diagnostic accuracy and turnaround speed.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589
⚙️ By Product & Service: Reagents, Kits, and Consumables Dominate the Market
The market is segmented into reagents, kits, and consumables; instruments; and software & services.
In 2024, reagents, kits, and consumables accounted for the largest market share and are expected to maintain dominance through 2030.
Why This Segment Leads:
- High testing frequency and recurring demand among end users
- Critical role in ensuring test reliability and sensitivity
- Continuous product innovation in multiplex assays and rapid test kits
- Increasing use of AI-enhanced molecular reagents for faster data interpretation
This recurring revenue stream is vital for diagnostic companies, as consumable purchases represent a stable, long-term growth opportunity.
💉 By Sample Type: Blood, Serum, and Plasma Lead Testing Applications
Based on sample type, the market is segmented into blood, serum, and plasma; urine; and other samples.
In 2024, blood, serum, and plasma samples dominated due to their rich diagnostic value and ability to reveal multiple biomarkers and pathogens.
These samples provide comprehensive biological data for PCR, ELISA, NGS, and immunodiagnostic assays, enabling healthcare professionals to:
- Detect infections in early stages
- Monitor disease progression
- Support personalized therapy planning
The continued evolution of liquid biopsy and microfluidic diagnostic platforms is expected to further enhance blood-based testing capabilities.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589
🧬 By Technology: Molecular Diagnostics Driving Accuracy and Speed
The infectious disease diagnostics market is transforming through the adoption of advanced molecular technologies, including:
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Isothermal Amplification
- Immunodiagnostics (ELISA, rapid antigen tests)
Emerging Trends:
- Miniaturized point-of-care PCR platforms
- Integration of AI-based image and data analysis
- Multi-pathogen syndromic testing panels
- Cloud-enabled diagnostic connectivity for remote healthcare settings
The fusion of molecular diagnostics with digital health technologies enables faster, decentralized testing, improving outbreak management and patient outcomes.
🏥 By Region: North America Leads Global Market Share
North America accounted for the largest share of the infectious disease diagnostics market in 2024, supported by:
- Advanced healthcare infrastructure
- High diagnostic testing rates
- Early adoption of AI and automation in laboratories
- Continuous R&D investment by leading diagnostic manufacturers
The United States remains a global innovation hub, driven by FDA approvals, strong public-private partnerships, and government initiatives to strengthen disease surveillance systems.
Meanwhile, the Asia Pacific region is expected to witness the fastest growth, supported by:
- Rapid healthcare modernization in China, India, and South Korea
- Expanding diagnostic access in rural and underserved areas
- Growing focus on infectious disease prevention and control programs
🧠 Innovation Spotlight: AI and Point-of-Care Diagnostics Revolutionizing Testing
Emerging technologies are transforming how healthcare providers detect and manage infectious diseases:
- AI-powered diagnostic platforms enhance test interpretation, reducing false negatives and improving clinical decision-making.
- Portable point-of-care devices enable testing in decentralized environments, from clinics to home care.
- Cloud-based connectivity supports real-time data sharing and outbreak monitoring.
- NGS-based pathogen identification facilitates comprehensive surveillance of evolving strains and resistance patterns.
These innovations are central to achieving global health resilience and precision-based public health strategies.
🧩 Key Market Players
Leading companies shaping the infectious disease diagnostics landscape include:
F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Danaher Corporation (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), and Bio-Rad Laboratories, Inc. (US).
These companies are investing in AI-enabled diagnostic automation, portable molecular testing, and syndromic panels, driving innovation across clinical and research applications.
🚀 Conclusion: Diagnostics at the Core of Global Health Preparedness
As infectious threats evolve, accurate, rapid, and decentralized testing has become essential to global health strategies.
The infectious disease diagnostics market is poised for sustained growth, powered by molecular innovations, AI-driven platforms, and expanding diagnostic infrastructure in both developed and emerging economies.
With increasing global health challenges, diagnostics remains the cornerstone of effective disease prevention, timely treatment, and population-level surveillance.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=116764589